A new monoclonal antibody targets a particular region of the receptor-binding domain (RBD) on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This region is usually not accessible to immune cells, which may be why it has broad neutralizing capabilities….
Read More
Targeted therapy achieves excellent outcomes, reduces side effects in high-risk Hodgkin lymphoma
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma. The study showed that the addition of brentuximab vedotin achieved excellent outcomes, reduced side effects, and allowed for reduced radiation…
Read More
Breath Analysis: How Could it Improve Healthcare and Diagnosis?
insights from industrySanti Dominguez & Michael GrazCEO & Acting CEOImspex Diagnostics & Imspex Medical In this interview, News-Medical talks to Santi Dominguez and Michael Graz, CEOs atImspex Diagnostics and Imspex Medical respectively, about the role breath analysis has to play…
Read More
Neutralizing antibodies to SARS-CoV-2 in mice depend on Fc effector function
The onset of the coronavirus disease 2019 (COVID-19) brought about intensive research on the biological characteristics of the pathogen responsible, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The immune response mediated by neutralizing antibodies, elicited by the virus or…
Read More
Novel host-viral-microbiome interactions during COVID-19 may determine outcome
The current pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been spreading rapidly for over a year. Though primarily a respiratory illness, its manifestations are often protean and may be life-threatening….
Read More
Concerning mutation in New York SARS-CoV-2 should be monitored, warn researchers
Researchers at the New York State Department of Health in the United States have said concerning mutations within the B.1.526 lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has recently become prevalent in New York State warrant further…
Read More
Studies reveal the promise of newly engineered bispecific antibodies against tumor cells
Three studies – one each in Science, Science Translational Medicine, and Science Immunology – reveal the promise of newly engineered bispecific antibodies, including by demonstrating their power against previously inaccessible tumor cell targets for the first time, in two cases….
Read More
Researchers evaluate surrogate large-scale SARS-CoV-2 serosurveillance test
A team of international scientists has recently evaluated a surrogate virus neutralization test for severe acute respiratory coronavirus 2 (SARS-CoV-2) and observed that it is highly efficacious for detecting anti-SARS-CoV-2 neutralizing antibodies in serum samples. According to the scientists, the…
Read More
Sample Preparation for Fluorescence Microscopy
By Shelley Farrar, MSc, BSc Fluorescence Microscopy allows specimens to be studied with high sensitivity and specificity through the use of light. It works on the principle that energy emitted by certain types of materials can be detected as light,…
Read More
Preclinical data on lead coronaviruses antibody
Adagio Therapeutics today published in vitro and in vivo data in Science on its lead antibody candidate, ADG2, which demonstrated similar or higher potency against SARS-CoV-2 compared to other monoclonal antibodies (mAbs) in clinical development and strong binding to all…
Read More